Ivonescimab Shows Promising Results in mCRC Clinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Source: Newsfilter
- Clinical Trial Results: In the recent AK112-206 trial, patients receiving ivonescimab combined with mFOLFOX6 chemotherapy achieved an objective response rate (ORR) of 70.8%, indicating the drug's potential in treating metastatic colorectal cancer (mCRC) and surpassing historical benchmarks for standard therapies.
- Tolerability and Safety: The safety profile of ivonescimab aligns with historical data, with 20.4% of patients experiencing serious treatment-related adverse events (TRAEs) but no new safety signals observed, suggesting good tolerability and suitability for further development.
- Durability of Efficacy: In the ivonescimab 20 mg/kg group, the duration of response landmark estimate at 9 months was 79.1%, compared to 41.5% in the 10 mg/kg group, indicating that the higher dose may offer better long-term survival prospects for patients.
- Future Research Directions: Summit is conducting the HARMONi-GI3 trial to evaluate the combined efficacy of ivonescimab with mFOLFOX6 chemotherapy, which is expected to provide new treatment options for patients with metastatic colorectal cancer and further advance the clinical development of this drug.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMMT
Wall Street analysts forecast SMMT stock price to rise
12 Analyst Rating
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 17.410
Low
18.00
Averages
42.49
High
131.90
Current: 17.410
Low
18.00
Averages
42.49
High
131.90
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ivonescimab Shows Promising Results in mCRC Clinical Development
- Clinical Trial Results: In the recent AK112-206 trial, patients receiving ivonescimab combined with mFOLFOX6 chemotherapy achieved an objective response rate (ORR) of 70.8%, indicating the drug's potential in treating metastatic colorectal cancer (mCRC) and surpassing historical benchmarks for standard therapies.
- Tolerability and Safety: The safety profile of ivonescimab aligns with historical data, with 20.4% of patients experiencing serious treatment-related adverse events (TRAEs) but no new safety signals observed, suggesting good tolerability and suitability for further development.
- Durability of Efficacy: In the ivonescimab 20 mg/kg group, the duration of response landmark estimate at 9 months was 79.1%, compared to 41.5% in the 10 mg/kg group, indicating that the higher dose may offer better long-term survival prospects for patients.
- Future Research Directions: Summit is conducting the HARMONi-GI3 trial to evaluate the combined efficacy of ivonescimab with mFOLFOX6 chemotherapy, which is expected to provide new treatment options for patients with metastatic colorectal cancer and further advance the clinical development of this drug.
See More
VERAXA Biotech Secures $27.5 Million Financing Agreement
- Financing Agreement Secured: VERAXA Biotech AG has entered into a securities purchase agreement with an institutional investor for $27.5 million, in addition to a $50 million share purchase agreement with Lincoln Park Capital Fund, significantly enhancing the company's liquidity.
- NASDAQ Listing Application: The company has applied for a NASDAQ listing under the ticker symbol “VRXA” through a merger with Voyager Acquisition Corp., aiming to accelerate the advancement of its cancer therapies pipeline, reflecting confidence in future growth prospects.
- Management Statement: CFO Torsten Bürgermeister stated that securing these financings marks a significant step in the ongoing business combination with Voyager Acquisition Corp., indicating a disciplined and flexible approach to capital management.
- Investor Support Acknowledged: The company expressed gratitude for the financial support from investors, emphasizing the importance of maintaining prudent financial management during ongoing capital acquisition efforts to ensure long-term growth and market competitiveness.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
H.C. Wainwright Downgrades Summit to Neutral Amid Trial Concerns
- Rating Downgrade: H.C. Wainwright downgraded Summit Therapeutics (SMMT) from Buy to Neutral, primarily due to concerns over the new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck in partnership with Kelun-Biotech.
- Clinical Trial Results: According to an ASCO abstract, the combination of sac-TMT and Merck's Keytruda reduced the risk of disease progression or death by 65% in lung cancer patients, demonstrating a statistically significant effect that could impact SMMT's market performance.
- Competitive Pressure: Analysts noted that Merck now has a credible defense for Keytruda's market position, particularly against Summit's ivonescimab, which previously showed strong performance in similar clinical settings.
- Delayed Survival Data: Concerns were raised regarding Akeso's delay in updating overall survival data, which, while showing favorable early trends, lacks statistical significance and is now expected to be released in 2026, potentially increasing market uncertainty.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
Ivonescimab Shows Promising Results in mCRC Clinical Development
- Clinical Trial Results: In the recent AK112-206 trial, patients receiving ivonescimab combined with mFOLFOX6 chemotherapy achieved an objective response rate (ORR) of 70.8%, indicating the drug's potential in treating metastatic colorectal cancer (mCRC) and surpassing historical benchmarks for standard therapies.
- Tolerability and Safety: The safety profile of ivonescimab aligns with historical data, with 20.4% of patients experiencing serious treatment-related adverse events (TRAEs) but no new safety signals observed, suggesting good tolerability and suitability for further development.
- Durability of Efficacy: In the ivonescimab 20 mg/kg group, the duration of response landmark estimate at 9 months was 79.1%, compared to 41.5% in the 10 mg/kg group, indicating that the higher dose may offer better long-term survival prospects for patients.
- Future Research Directions: Summit is conducting the HARMONi-GI3 trial to evaluate the combined efficacy of ivonescimab with mFOLFOX6 chemotherapy, which is expected to provide new treatment options for patients with metastatic colorectal cancer and further advance the clinical development of this drug.
See More
VERAXA Biotech Secures $27.5 Million Financing Agreement
- Financing Agreement Secured: VERAXA Biotech AG has entered into a securities purchase agreement with an institutional investor for $27.5 million, in addition to a $50 million share purchase agreement with Lincoln Park Capital Fund, significantly enhancing the company's liquidity.
- NASDAQ Listing Application: The company has applied for a NASDAQ listing under the ticker symbol “VRXA” through a merger with Voyager Acquisition Corp., aiming to accelerate the advancement of its cancer therapies pipeline, reflecting confidence in future growth prospects.
- Management Statement: CFO Torsten Bürgermeister stated that securing these financings marks a significant step in the ongoing business combination with Voyager Acquisition Corp., indicating a disciplined and flexible approach to capital management.
- Investor Support Acknowledged: The company expressed gratitude for the financial support from investors, emphasizing the importance of maintaining prudent financial management during ongoing capital acquisition efforts to ensure long-term growth and market competitiveness.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
H.C. Wainwright Downgrades Summit to Neutral Amid Trial Concerns
- Rating Downgrade: H.C. Wainwright downgraded Summit Therapeutics (SMMT) from Buy to Neutral, primarily due to concerns over the new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck in partnership with Kelun-Biotech.
- Clinical Trial Results: According to an ASCO abstract, the combination of sac-TMT and Merck's Keytruda reduced the risk of disease progression or death by 65% in lung cancer patients, demonstrating a statistically significant effect that could impact SMMT's market performance.
- Competitive Pressure: Analysts noted that Merck now has a credible defense for Keytruda's market position, particularly against Summit's ivonescimab, which previously showed strong performance in similar clinical settings.
- Delayed Survival Data: Concerns were raised regarding Akeso's delay in updating overall survival data, which, while showing favorable early trends, lacks statistical significance and is now expected to be released in 2026, potentially increasing market uncertainty.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
